Preventive and therapeutic DNA vaccination partially protect dogs against an infectious challenge with Trypanosoma cruzi

Reservoir host competence and the role of domestic and commensal hosts in the transmission of Trypanosoma cruzi

“…Dogs experimentally infected with T. cruzi and vaccinated with T. rangeli antigens had reduced parasitemia and infectiousness (Basso et al, 2007). A preventive and therapeutic DNA vaccine reduced parasitemia, cardiac inflammation and cardiac parasite burden in experimentally-infected mongrel dogs (Quijano-Hernández et al, 2013). A combined approach that identifies the most infectious dogs and treats them with an effective therapeutic vaccine suppressing infectiousness is predicted to strongly reduce the risk of infection in vectors and other domestic hosts.…”

Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease

“…24 A DNA vaccine containing the Tc24 coding sequence has likewise shown efficacy when introduced into T. cruzi infected mice and dogs. [25][26][27][28] Based on the fact that no human DNA vaccine has yet been registered or licensed, we are pursuing Chagas vaccine development through a recombinant protein-based approach. Recently, a study has been published where vaccination of mice with wild-type Tc24 (Tc24-WT) using MPLA as the adjuvant, induced a Th1-biased immune response, which provided partial protection after T. cruzi challenge.…”

Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine againstTrypanosoma cruziinfection

“…Research on and developments of therapeutic vaccines are especially important in Chagas disease considering the characteristic mammal chronic infection and the number of people living in the Americas with a parasite infection for decades. In experimental T. cruzi infection, Dumonteil et al 25,26 demonstrated that an intramuscular injection of plasmid DNA encoding TSA-1 or Tc24 protected infected mice.…”

“…13 Recent improvements to DNA vaccines and the potential and flexibility of DNA as a potent immunization strategy for inducing both humoral and cell-mediated immune responses, make them an ideal therapeutic approach for treating or eliminating chronic disease, as it was shown in multiple sclerosis, 14 human papillomavirus, 15,16 hepatitis B 17 , human immunodeficiency virus, 18,19 simian immunodeficiency virus, 20 Mycobacterium tuberculosis, 21 Leishmania spp., 22,23 Schistosoma mansoni, 24 as well as against T. cruzi. 25,26 We have previously reported the efficacy of attenuated Salmonella enterica (S) carrying plasmid encoding cruzipain (SCz) to protect against T. cruzi infection. 27,28 In the present work we investigated whether Cz DNA vaccine immunotherapy could be effective in controlling an ongoing T. cruzi infection in mice.…”